Higher dose of Crohn's drug shows promise for tough cases

NCT ID NCT00805766

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a higher dose (10 mg/kg) of the drug infliximab (TA-650) could help people with Crohn's disease who were not getting enough benefit from the standard dose (5 mg/kg). The 39 participants received the higher dose every 8 weeks. The main goal was to see if their symptoms, measured by a standard Crohn's disease activity index, improved significantly after 8 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE

Contacts and locations

Locations

Investigational site

Hokkaido, Japan
Investigational site

Kansai, Japan
Investigational site

Kanto, Japan
Investigational site

Kyushu, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.